This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech ETF Tops in June: 5 Stocks That Outperform
by Sweta Killa
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.
4 Sector ETFs That Survived Market Turmoil in June
by Sweta Killa
June has proved to be a brutal month for the stock market. The combination of factors such as decades-high inflation, the Russia-Ukraine conflict and Fed¿¿¿s aggressive tightening policy are weighing heavily on investors' sentiment.
ETFs Winners of S&P 500's Second Best Week in 2022
by Sanghamitra Saha
The S&P 500 advanced more than 3% on Friday, logging back-to-back days of gains and marking its first weekly advance since late May.
Top and Flop ETFs of Q1
by Sweta Killa
We have highlighted the three ETFs each from the best and worst performing zones of first-quarter 2022.
Top and Flop ETFs At Midway Q1
by Sweta Killa
We have highlighted the five best-performing zones and their ETFs halfway through first-quarter 2022.
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News
by Sweta Killa
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
by Sweta Killa
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal
by Sweta Killa
These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Biotech ETFs Soars on Gilead-Immunomedics Deal
by Sweta Killa
The acquisition will expand Gilead's portfolio of treatments for various types of cancer.
Why Small-Cap Biotech ETFs Are Good Long-Term Bets
by Sanghamitra Saha
Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.
4 Best ETF Charts of Q1 Earnings
by Sweta Killa
Below are four ETFs that buoyed up on strong earnings results.
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain
by Sweta Killa
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
Biotech ETF (BBC) Hits a New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Top ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week, mainly driven by these ETF areas.
5 Market-Beating Smart-Beta ETF Charts of 2019
by Sanghamitra Saha
These smart-beta ETFs beat the broader market with ease in 2019.
A Banner Year for Stocks
by Neena Mishra
Major indexes are on track for their best annual performance in six years, powered by tech companies
Biotech Rally Sends Nasdaq to 9000: ETFs in Focus
by Sanghamitra Saha
Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.
9 ETFs at the Forefront of 2019 Market Rally
by Sweta Killa
As there have been winners in many corners of the space, we highlight nine ETFs from different zones that have outperformed so far this year. These are expected to continue outperforming, provided the fundamentals remain intact.
Best & Worst ETFs of Fourth Quarter
by Sanghamitra Saha
Inside the top and worst-performing ETFs of the fourth quarter.
4 Sector ETFs That Beat the Market in Q4
by Sanghamitra Saha
While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.
Biotech Leading in Q4: Best ETFs & Stocks
by Sweta Killa
We highlight five biotech ETFs and stocks that are leading the market in Q4.
Will Biotech ETFs Excel in Election Year Post a Surge in 2019?
by Sanghamitra Saha
Can biotech ETFs repeat its success story of 2019 in the election year of 2020?
5 Market-Beating Sector ETFs of 2019
by Sweta Killa
Braving all hurdles including recession fears, trade dispute, Brexit and geopolitical tensions, Wall Street has enjoyed a huge rally this year with all the three major indices hitting record highs lately.